Addressing the Challenges of Hepatitis C Virus Resistance and Treatment Failure
AbstractChronic hepatitis C is a major cause of chronic liver disease, including liver cirrhosis and hepatocellular carcinoma. The development of direct-acting antivirals (DAAs) revolutionized hepatitis C virus (HCV) treatment by offering genuine prospects for the first comprehensive cure of a chronic viral infection in humans. While antiviral resistance is a significant limitation for interferon-based therapies, resistance and treatment failure still appear to be present in a small fraction of patients even in state-of-the-art DAA combination therapies. Therefore, treatment failure and resistance still remain a clinical challenge for the management of patients not responding to DAAs. In this special issue of Viruses on HCV drug resistance, mechanisms of antiviral resistance for different classes of antiviral drugs are described. Furthermore, the detection and monitoring of resistance in clinical practice, the clinical impact of resistance in different patient groups and strategies to prevent and address resistance and treatment failure using complementary antiviral strategies are reviewed. View Full-Text
Share & Cite This Article
Colpitts, C.C.; Baumert, T.F. Addressing the Challenges of Hepatitis C Virus Resistance and Treatment Failure. Viruses 2016, 8, 226.
Colpitts CC, Baumert TF. Addressing the Challenges of Hepatitis C Virus Resistance and Treatment Failure. Viruses. 2016; 8(8):226.Chicago/Turabian Style
Colpitts, Che C.; Baumert, Thomas F. 2016. "Addressing the Challenges of Hepatitis C Virus Resistance and Treatment Failure." Viruses 8, no. 8: 226.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.